ENDRA Life Sciences, Inc. NDRA 深 滬
已收盤 10-17 16:00:00 美东时间
6.13
-0.870
-12.43%
華盛通- 最 高7.1695
- 今 開6.73
- 成交量 9.79万股
- 最 低 6.13
- 昨 收 7.00
- 總市值 461.47万
- 52周最高 12.4915
- 市盈率 靜 --
- 換手率 13.01%
- 52周最低 2.90
- 委 比 88.67%
- 總股本 75.28万
- 歷史最高 205800.00
- 量 比 0.03
- 振 幅 14.85%
- 歷史最低 2.90
- 每 手 1
- 風險率 28.27%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Strata Skin Sciences (NASDAQ:SSKN) shares increased by 44.9% to $2.23 ...
10-15 01:06
Robinhood Weighs Prediction-Market Acquisitions: Report
Robinhood Markets, Inc. (NASDAQ:HOOD) shares traded lower in the premarket sess...
10-14 21:43
Why Ericsson Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket
Shares of Telefonaktiebolaget LM Ericsson – ADR (NASDAQ:ERIC) rose sharply in p...
10-14 17:45
ENDRA Life Sciences Gains Momentum With Crypto-Focused Treasury Plan
ENDRA Life Sciences Inc. (NASDAQ: NDRA) announced $4.9M in funding to launch a digital asset treasury strategy.
10-14 00:24
美股大行评级 | 潜在涨幅1650.0%！Ascendiant Capital维持GRI Bio"买入"评级，目标价上调至35美元
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从34美元升至35美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.5美元升至7.75美元
09-23 09:52
Ascendiant Capital Maintains Buy on ENDRA Life Sciences, Lowers Price Target to $38
Ascendiant Capital analyst Edward Woo maintains ENDRA Life Sciences (NASDAQ:NDRA) with a Buy and lowers the price target from $46 to $38.
09-22 17:54
净利腰斩！ 水井坊“寒冬”：胡庭洲首份半年成绩单“不及格” | 酒业内参
文 | 酒业内参 张奥 水井坊近期公布了2025年半年报：实现营业收入14.98亿元，同比下降12.84%；净利润1.05亿元，同比下降56.52%。若...
09-02 08:49
ENDRA Life Sciences Q2 EPS $(1.71) Beats $(2.27) Estimate
ENDRA Life Sciences (NASDAQ:NDRA) reported quarterly losses of $(1.71) per share which beat the analyst consensus estimate of $(2.27) by 24.67 percent. This is a 2037.5 percent decrease over losses of $(0.08) per share
08-15 04:17
快讯 | ENDRA生命科学公司第二季度运营支出为120万美元
ENDRA Life Sciences Q2 Operating Expenses USD 1.2 Million
08-15 04:05
ENDRA Life Sciences Launches Bitcoin Treasury Strategy, Forms Advisory Board With James Altucher, James Manning, And Rayne Steinberg
The Board of Directors (the "Board") of ENDRA Life Sciences Inc. (the "Company") has authorized the Company to develop and pursue a cryptocurrency treasury strategy. Following this authorization, the Company has:
07-23 21:08
